Approximately 170 million people are infected with hepatitis C virus (HCV) worldwide. This infection has been the cause of chronic hepatitis, cirrhosis, and hepatocellular carcinoma. Blood-transfused individuals and patients who have undergone invasive medical procedures such as hemodialysis have been considered to be at high risk for hepatitis C infection (Chen & Morgan 2006) . These patients have an increased tendency to become chronic carriers of HCV and also to be potential disseminators of this agent in the hemodialytic environment (Izopet et al. 2005 , Hmaied et al. 2006 . In addition, hepatitis C seems to increase the mortality rate of this group of patients (Meyers et al. 2003) .
HCV is classified into six major genetic groups, designated genotypes 1 to 6, each comprising multiple subtypes (designated a, b, c, etc) . These genotypes have distinct geographical distributions. Genotype determination is a relevant predictive parameter of the response to antiviral treatment. Furthermore, the genotyping of HCV isolates is a useful tool in molecular studies carried out to establish the source of outbreaks in hemodialysis centers and other nosocomial settings (Zein 2000) .
The prevalence of HCV antibodies has been reported to range from 3% in hemodialysis patients in the USA to more than 70% in Eastern Europe (Vladutiu et al. 2000 , Finelli et al. 2005 . In Brazil, a country of continental dimensions, HCV infection has not been fully investigated among hemodialysis patients. Some studies have found HCV prevalence rates to range from 8.4% to 65% ( Vanderborght et al. 1995 , Mello et al. 2007 ). In the state of Mato Grosso do Sul, there is no data about this infection in patients undergoing hemodialysis. Therefore, this study is the first to investigate the HCV infection prevalence, risk factors, and genotypes in hemodialysis patients in the city of Campo Grande, the capital of the state of Mato Grosso do Sul in the Mid-west region of Brazil.
This investigation was carried out in the five hemodialysis units of Campo Grande, in 2003. The study sample size was calculated based on an alpha error of 5%, an expected anti-HCV prevalence of 13% (Souza et al. 2003) , and a precision of 5%. In accordance with these data, the sample size necessary was 174 patients. Study participants were recruited using a systematic sampling method, according to the proportion of patients by unit. The protocol used in this study was approved by the Ethical Committee of the Universidade Federal de Mato Grosso do Sul. Informed consent was obtained from all participants (or their parents for children).
A total of 163 (93.7%) patients participated in the study. Initially, all participants were interviewed in order to obtain sociodemographic data and risk factors associated with HCV infection. The study population ranged in age from 13 to 83 years (mean age 48 years). Ninety-seven participants (59.5%) were males and 66 (40.5%) were females. Most of the participants (80%) were of low socioeconomic (families with monthly income less than US$ 200) and education levels (less than eight years of formal education). All subjects received treatment three times a week and were distributed into two or three shifts depending on their dialysis unit. Hemodialysis was performed with bicarbonate and cuprophane or polysulphone dialyzers. These and the bloodlines were disinfected and reused by the same patient. Hemodialysis machines were disinfected at the end of the day, and equipment surfaces were disinfected after each session.
Blood samples were collected from all participants, and serum samples were tested for anti-HCV by a thirdgeneration enzyme-linked immunoassay (ELISA) (Innotest HCV Ab III, Innogenetics, Ghent, Belgium). Anti-HCV reactive samples were retested by a line immunoassay (LIA) (INNO-LIA HCV Ab III, Innogenetics). Positive anti-HCV samples were submitted for RNA extraction, reverse transcription, and a nested PCR with primers complementary to the conserved area of the 5' non-coding region of HCV ). Positive samples were genotyped by "line probe assay" (INNO-LiPA HCV, Innogenetics NV, Ghent, Belgium).
The prevalence of infection with 95% confidence intervals (95% CI) was calculated. Chi-square and Fisher tests were used to evaluate the risk factors associated with HCV infection (defined as positive for anti-HCV). Statistical significance was assessed at the 0.05 probability level in all analyses. Risk factors, first estimated by odds ratio in univariate analysis, were analyzed subsequently by multiple logistic regression. Statistical analysis was performed using Epiinfo program, version 2000 package developed by the Centers for Disease Control and Prevention (Atlanta, GA).
Of the 163 studied patients, 19 (11.7%) were found to be anti-HCV positive by ELISA, and 18 were subsequently confirmed as being positive by LIA, resulting in an overall anti-HCV prevalence of 11% (95% CI: 6.8-17.1), ranging from 0% to 28.6% depending on the dialysis unit. HCV RNA was detected in 12/18 (67%) of the anti-HCV positive patients. Ten samples were genotyped as genotype 1, subtypes 1a (75%) and 1b (8.3%), and two samples (16.7%) as genotype 3, subtype 3a.
An analysis of the risk factors showed that a history of transfusion with blood not screened for anti-HCV (before November 1993), the length of time on hemodialysis, and having treatment in multiple units were significantly associated with HCV infection by univariate analysis. These factors were included in a logistic regression model, which showed that a history of transfusion with blood not screened for anti-HCV and a duration of hemodialysis greater than seven years were independently associated with HCV infection (Table) . Interestingly, in the state of Goiás, located in the same region of Brazil, a study that investigated hepatitis B virus (HBV) infection in the hemodialysis patient population (Ferreira et al. 2006 ) also found that the same risk factors were independently associated with HBV infection; this implies that HCV is disseminated among hemodialysis patients in a similar fashion as HBV in these states.
In this investigation, the prevalence of HCV infection in hemodialysis patients in the city of Campo Grande was almost eight times greater than that observed in blood donors from the same region (Martins et al. 1994) . Nevertheless, in comparison with other hemodialysis populations in Mid-west region of Brazil, this was similar to those found in the states of Goiás (16.4%; 95% CI: 14.3-18.7) ) and Mato Grosso (16.9%; 95% CI: 13.3-20.8) (Santos & Souto 2007) . These findings were also in accordance with other Brazilian investigations, in which the prevalence has varied from 8.4% to 65% (Vanderborght et al. 1995 , Mello et al. 2007 ). In contrast, this anti-HCV prevalence rate was higher than those found in investigations carried out in other countries such as Germany (7%) (Hinrichisen et al. 2002) , the US (7.8%) (Finelli et al. 2005 ), Spain (6.8%) (Gallego et al. 2006 ) and the UK (3%) (Jadoul et al. 2004 ). However, the seroprevalence detected was lower than that of India (30%) (Jaiswal et al. 2002) , Japan (15%) (Furusyo et al. 2001) , France (30%) and Poland (44%) (Jadoul et al. 2004) , ratifying the high prevalence of hepatitis C in hemodialysis patients.
The distribution of HCV genotype in the study population, with a predominance of subtype 1a followed by 1b and 3a, differs from that of local blood donors, in which subtypes 1a and 1b were detected equally (36.8%), followed by 3a (21.1%) and 2b (5.3%) ). However, the predominance of genotype 1, subtype 1a was also found in other Brazilian studies carried out among hemodialysis patients of São Paulo (Moreira et al. 2003 , Perez et al. 2003 , Tocantins (Souza et al. 2003) , Recife (Albuquerque et al. 2005) and Goiás . Significantly, most patients infected with HCV subtype 1a were receiving treatment at the same hemodialysis unit in Campo Grande. Similarly, this genotype is also predominant among hemodialysis patients of other countries such as the United States (Chen & Weck 2002) and Jordan (Bdour 2002) . As observed by other authors (Salama et al. 2000 , Albuquerque et al. 2005 , two variables were independently associated with HCV infection in our patients: blood transfusion before screening for anti-HCV and length of time on hemodialysis treatment. The first finding clearly demonstrates the impact of screening for anti-HCV in candidates for blood donation, while the second reinforces the notion of the hemodialytic environment as a source of HCV dissemination. In fact, patients who had previously received a blood transfusion that was not screened for anti-HCV presented a 12.3-fold greater risk of HCV infection when compared with those that were transfused with screened blood, but the first group constituted only a minority of the patients from this study. For the majority of HCV-infected patients who received blood transfusion screened for anti-HCV, the most probable risk factor was hemodialysis treatment. Moreover, the association between the length of time on hemodialysis and HCV infection, with a greater risk (58.1-fold) for patients under treatment for more than seven years when compared to those who had undergone less than five years of treatment, reinforces the probability of nosocomial transmission in the studied units.
In Brazil, infection control measures in hemodialysis units became mandatory after 1996 as consequence of new Health Ministry standards for renal units (Ministério da Saúde 1996) . Although the prevalence of HCV infection found in the present investigation is still high, it was markedly lower than the alarming prevalence of 65% found in hemodialysis patients in Rio de Janeiro (Vanderborght et al. 1995) before the implementation of new rules for Brazilian renal units. In fact, this infection has declined after hemodialysis-specific infection control measures were adopted in Brazilian units (Carneiro et al. 2005) . Nevertheless, the legacy of negligence has provided a significant HCV reservoir among chronic renal patients, who at any time may cause outbreaks of hepatitis C unless stricter hygiene measures are not fully enforced.
In summary, although the prevalence of HCV infection in hemodialysis patients in the city of Campo Grande is similar to those recently found in other Brazilian hemodialysis units, it is still high when compared with the prevalence among blood donors from the same region. The finding that the length of time on hemodialysis is associated with anti-HCV positivity suggests nosocomial transmission. The predominance of genotype 1, subtype 1a of HCV in this population corroborates this hypothesis, reinforcing the need for stricter adherence to infection control measures in dialysis units.
